28th May 2015 08:08
LONDON (Alliance News) - Pharmaceuticals and pharmaceuticals services company Clinigen Group PLC on Thursday said it has launched a global-access programme in Europe for rociletinib, a drug being developed for the treatment of advanced non-small cell lung cancer by Clovis Oncology.
Clinigen said the programme is intended to allow access to rociletinib for patients with advanced or metastatic epidermal growth factor receptor-mutant T790M-positive non-small cell lung cancer who have previously been treated with an EGFR-targeted therapy and for whom their doctor determines that there is no satisfactory alternative therapy or rociletinib clinical trial available.
"Non-small cell lung cancer is a devastating disease affecting a huge number of people worldwide. Our experience in managing access programs on a global scale will enable us to provide critically ill patients with rapid access to rociletinib before it is commercially available. We look forward to working with Clovis to address this area of unmet medical need," said Simon Estcourt, managing director of Clinigen's managed access programmes.
Shares in Clinigen were up 1.2% to 639.275 pence on Thursday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
CLIN.L